M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease.
Paolo Calabrò,Felice Gragnano,Giampaolo Niccoli,Rossella Marcucci,Marco Zimarino,Carmen Spaccarotella,Giulia Renda,Giuseppe Patti,Giuseppe Andò,Elisabetta Moscarella,Massimo Mancone,Arturo Cesaro,Gennaro Giustino,Raffaele De Caterina,Roxana Mehran,Davide Capodanno,Marco Valgimigli,Stephan Windecker,George Dangas,Ciro Indolfi,Dominick J. Angiolillo +20 more
TL;DR: In this article, aortic valve implantation, mitral valve insertion, and mitral bypass were performed for patients with structural heart disease, using device-based transcatheter interventions.
Journal Article
Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis
Laura Gramantieri,Pasquale Chieco,Di Tomaso M,Livia Masi,Fabio Piscaglia,Stefano Brillanti,Stefano Gaiani,Marco Valgimigli,A. Mazziotti,Luigi Bolondi +9 more
TL;DR: Patients with aberrant FHIT transcripts showed a significantly higher relapse rate and shorter recurrence time, which could be related to a primary genomic instability affecting particularly susceptible regions like FRA3B and could be associated with an increasing risk of recurrence without involving a causative role.
Journal ArticleDOI
Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome.
Giuseppe Gargiulo,Greta Carrara,Enrico Frigoli,Sergio Leonardi,Pascal Vranckx,Gianluca Campo,Ferdinando Varbella,Paolo Calabrò,Tiziana Zaro,Davide Bartolini,Carlo Briguori,Giuseppe Andò,Maurizio Ferrario,Ugo Limbruno,Salvatore Colangelo,Paolo Sganzerla,Filippo Russo,Marco Stefano Nazzaro,Giovanni Esposito,Giuseppe Ferrante,Andrea Santarelli,Gennaro Sardella,Stephan Windecker,Marco Valgimigli +23 more
TL;DR: In this paper, the authors evaluated efficacy and safety of a full or low post-PCI bivalirudin regimen in acute coronary syndrome (ACS) patients with or without ST-segment elevation.
Journal ArticleDOI
Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials
Salvatore Cassese,Sebastian Kufner,Erion Xhepa,Robert A. Byrne,Johanna Kreutzer,Tareq Ibrahim,Klaus Tiroch,Marco Valgimigli,Ralph Tölg,Massimiliano Fusaro,Heribert Schunkert,Karl-Ludwig Laugwitz,Julinda Mehilli,Adnan Kastrati +13 more
TL;DR: At 3-year follow-up, a PCI with new- generation DES for uLMCA disease shows comparable efficacy to early-generation DES, and diabetes significantly impacts the risk of MACCE.
Journal ArticleDOI
Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice
Christian Zanchin,Yasushi Ueki,Thomas Zanchin,Jonas Dominik Häner,Tatsuhiko Otsuka,Stefan Stortecky,Konstantinos C. Koskinas,George C.M. Siontis,Fabien Praz,Aris Moschovitis,Lukas Hunziker,Marco Valgimigli,Thomas Pilgrim,Dik Heg,Stephan Windecker,Lorenz Räber +15 more
TL;DR: No difference in the device-oriented composite endpoint between BP-E ES and DP-EES was observed throughout 12 months, and there was a higher rate of acute stent thrombosis with the BP- EES, a difference that disappeared at 1 year.